Spruce Biosciences, Inc
sprucebio.comSpruce Biosciences, Inc. (NASDAQ: SPRB) is a clinical-stage biopharmaceutical company focused on developing enzyme replacement therapies for rare genetic diseases. The company generates no product revenue, operating entirely on capital raised through equity financing while advancing its pipeline toward regulatory approval. Its lead program, TA-ERT, targets mucopolysaccharidosis type IIIB (MPS IIIB), an ultra-rare neurodegenerative disease, with a Biologics License Application (BLA) submission planned for the fourth quarter of 2026 under the FDA's accelerated approval pathway, citing CSF heparan sulfate non-reducing end (CSF HS-NRE) as a reasonably likely surrogate endpoint. If approved, the company intends a potential commercial launch in mid-2027. CEO Javier Szwarcberg, M.D., MPH leads the organization. The company operates within the orphan disease drug development space and is subject to both FDA and EMA regulatory frameworks, with EU orphan designation providing potential market exclusivity protections.
Products & Services
TA-ERT: an enzyme replacement therapy in clinical development for the treatment of MPS IIIB (mucopolysaccharidosis type IIIB), a rare neurodegenerative lysosomal storage disorder. BLA submission targeted for Q4 2026 under FDA accelerated approval pathway.
Revenue Model
Spruce Biosciences has no approved products and generates no product revenue as of the 10-K filed 2026-03-09. Operations are funded through capital markets financing. Future revenue, if any, would depend on regulatory approval and commercialization of TA-ERT.
Customers & Markets
Target patient population: individuals with MPS IIIB, an ultra-rare pediatric neurodegenerative disease. End markets include rare disease and orphan drug segments in the United States and European Union.
Geographic Exposure
Primary regulatory focus on the United States (FDA) and European Union (EMA). No commercial geographic footprint disclosed as of the 10-K filed 2026-03-09.
Financial Snapshot
Loading...
